Research
Hormonal
Semaglutide 2.4 mg was associated with significantly greater weight loss compared to placebo in clinical trials lasting 68 weeks.
Semaglutide can be considered an effective pharmacotherapy for weight loss in adults with obesity or overweight.
StrongSupportsmedium confidence
In these 68-week trials, semaglutide 2.4 mg was associated with significantly greater weight loss compared to placebo.
Why this rating
Based on the mention of clinical trials, which are high-quality evidence.
Source
Semaglutide for Weight Loss: Was It Worth the Weight?
Joel Novograd et al. · Cardiology in Review · 2022
DOI 10.1097/crd.0000000000000430
reviewCited 14×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →